Vitamins that may be helpful
Inositol hexaniacinate (IHN), a special
form of vitamin B3, has been used successfully to treat intermittent claudication. The alleged
advantage of IHN over niacin (another form of vitamin B3) is a lower risk of toxicity. A
double-blind trial explored the effect of 2 grams of IHN taken twice per day for three
months.5 In nonsmokers and in people with unchanged smoking habits, the increase in
walking distance was significantly greater in the IHN group than in the placebo group. Other
double-blind research has confirmed IHN’s ability to improve symptoms of intermittent
claudication compared with placebo.6 This treatment should be monitored by a
doctor.
In double-blind trials, supplementation with either L-carnitine and propionyl-L-carnitine (a form of
L-carnitine) has increased walking distance in people with intermittent claudication. Walking
distance was 75% greater after three weeks of L-carnitine supplementation (2 grams taken twice
per day), than after supplementation with a placebo, a statistically significant
difference.7 In the study using propionyl-L-carnitine, improvement occurred only in
those who could not walk 250 meters to begin with. In that group, maximum walking distance
increased by 78% with propionyl-L-carnitine supplementation compared with a 44% increase in
the placebo group, also a statistically significant difference.8 The amount of
propionyl-L-carnitine used was 1 gram per day, increasing to 2 grams per day after two months,
and 3 grams per day after an additional two months, if needed. The results of this trial have
been confirmed in a large European trial.9
Men with intermittent claudication consumed a fortified milk product or regular milk daily for one year. The
fortified product provided daily 130 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic
acid (EPA and DHA, two fatty acids in fish
oil), small amounts of supplemental vitamin
E, folic acid, and vitamin B6, and additional amounts of oleic acid and
alpha-linolenic acid. Compared with regular milk, the fortified milk product significantly
increased the distance the participants could walk before the onset of pain.10
Policosanol, taken in the amount of 10 mg
twice a day for at least six months, increases pain-free walking capacity by over 50% in
people with intermittent claudication according to two double-blind trials.11
12 When policosanol was taken continuously for two years, walking capacity more than
doubled.13 This effect may be related to the ability of policosanol to reduce the
stickiness of platelets,14 15 16 which could result in
improved circulation.
Vitamin E supplementation has been shown in
controlled trials to increase both walking distance and blood flow through arteries of the
lower legs in people with intermittent claudication.17 18 Increasing
dietary intake of vitamin E was also associated with better blood flow to the
legs.19 Some early studies did not find vitamin E useful. Possibly this failure was
due to the short duration of the studies,20 as one review article suggested that a
minimum of four to six months of vitamin E supplementation may be necessary before significant
improvement is seen.21 Most clinical trials of vitamin E and intermittent
claudication used 400 to 600 IU per day, although one study used 2,400 IU per day.
Intravenous injections of the amino acid
arginine have been shown to be remarkably effective at improving intermittent
claudication. In a double-blind trial, 8 grams of arginine, injected twice daily for three
weeks, improved pain-free walking distance by 230% and absolute walking distance by 155%,
compared to no improvement with placebo.22 To date, no trials have examined the
effects of oral arginine supplementation on intermittent claudication.
Magnesium may increase blood flow by
helping to dilate blood vessels. A preliminary trial found that magnesium supplementation may
increase walking distance in people with intermittent claudication.23 Many doctors
suggest that people with atherosclerosis,
including those with intermittent claudication, take approximately 250 to 400 mg of magnesium
per day.
In a preliminary trial, supplementing with
evening primrose oil (approximately 1,600 mg per day) led to a 10% increase in exercise
tolerance in people with intermittent claudication.24
Caution: One study showed a slightly increased risk of vascular
surgery among people with intermittent claudication who took beta-carotene supplements.25 Until more is
known, people with intermittent claudication wishing to use beta-carotene supplements should
first consult with their doctor.
Are there any side effects or interactions?
Refer to the individual supplement for information about any side effects or interactions.
1. Cahan MA, Montgomery P, Otis RB, et al. The effect of cigarette
smoking status on six-minute walk distance in patients with intermittent claudication.
Angiology 1999;50:537–46.
2. Gardner AW, Womack CJ, Montgomery PS, et al. Cigarette smoking
shortens the duration of daily leisure time physical activity in patients with intermittent
claudication. J Cardiopulm Rehabil 1999;19:43–51.
3. Walker RD, Nawaz S, Wilkinson CH, et al. Influence of upper-
and lower-limb exercise training on cardiovascular function and walking distances in patients
with intermittent claudication. J Vasc Surg 2000;31:662–9.
4. Gardner AW, Katzel LI, Sorkin JD, et al. Improved functional outcomes
following exercise rehabilitation in patients with intermittent claudication. J Gerontol A
Biol Sci Med Sci 2000;55:M570–7.
5. Kiff RS, Wuick CRG. Does inositol nicotinate (Hexopal) influence
intermittent claudication?—a controlled trial. Br J Clin Pract
1988;42:141–5.
6. O’Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of
inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. Br J Clin
Pract 1988;42:377–83.
7. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking
distance in patients with peripheral vascular disease treated with L-carnitine: a
double-blind, cross-over study. Circulation 1988;77:767–73.
8. Brevetti G, Perna S, Sabba C, et al. Effect of propionyl-L-carnitine
on quality of life in intermittent claudication. Am J Cardiol
1997;79:777–80.
9. Brevetti G, Diehm C, Lambert D. European multicenter study on
propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol
1999;34:1618–24.
10. Carrero JJ, Lopez-Huertas E, Salmeron LM, et al. Daily
supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases
pain-free walking distance and improves risk factors in men with peripheral vascular disease.
J Nutr 2005;135:1393–9.
11. Castano G, Mas Ferreiro R, Fernandez L, et al. A long-term study of
policosanol in the treatment of intermittent claudication. Angiology
2001;52:115–25.
12. Castano G, Mas R, Roca J, et al. A double-blind, placebo-controlled
study of the effects of policosanol in patients with intermittent claudication.
Angiology 1999;50:123–30.
13. Castano G, Mas Ferreiro R, Fernandez L, et al. A long-term study of
policosanol in the treatment of intermittent claudication. Angiology
2001;52:115–25.
14. Carbajal D, Arruzazabala ML, Valdes S, Mas Ferreiro R. Effect of
policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in
healthy volunteers. Prostaglandins Leukot Essent Fatty Acids 1998;58:61–4.
15. Arruzazabala ML, Valdes S, Mas R, et al. Comparative study of
policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation
in healthy volunteers. Pharmacol Res1997;36:293–7.
16. Arruzazabala ML, Valdes S, Mas R, et al . Effect of policosanol
successive dose increases on platelet aggregation in healthy volunteers. Pharmacol
Res 1996;34:181–5.
17. Haeger K. Long-time treatment of intermittent claudication with
vitamin E. Am J Clin Nutr 1974;27:1179–81.
18. Williams HT, Fenna D, Macbeth RA. Alpha tocopherol in the treatment
of intermittent claudication. Surg Gynecol Obstet 1971;Apr:662–6.
19. Donnan PT, Thomson M, Fowkes GR, et al. Diet as a risk factor for
peripheral arterial disease in the general population: the Edinburgh Artery Study. Am J
Clin Nutr 1993;57:917–21.
20. Livingstone PD, Jones C. Treatment of intermittent claudication with
vitamin E. Lancet 1958;ii:602–4 [review].
21. Piesse JW. Vitamin E and peripheral vascular disease. Int Clin
Nutr Rev 1984;4:178–82 [review].
22. Boger RH, Bode-Boger SM, Thiele W, et al. Restoring vascular nitric
oxide formation by L-arginine improves the symptoms of intermittent claudication in patients
with peripheral arterial occlusive disease. J Am Coll Cardiol
1998;32:1336–44.
23. Neglen P, Overfordt P, Eklof B. Peroral magnesium hydroxide therapy
and intermittent claudication. Vasa 1985;14:285–8.
24. Christie SB, Conway N, Pearson HE. Observations on the performance of
a standard exercise test by claudicants taking gamma-linolenic acid. J Atheroscler
Res 1968;8:83–90.
25. Törnwall ME, Virtamo J, Haukka JK, et al. The effect of
alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent
claudication in a controlled trial. Atherosclerosis 1999;147:193–7.
26. Schneider B. Ginkgo biloba extract in peripheral arterial disease.
Meta-analysis of controlled clinical trials. Arzneimittelforschung
1992;42:428–36 [in German].
27. Peters H, Kieser M, Hölscher U. Demonstration of the efficacy of
Ginkgo biloba special extract EGb 761® on intermittent claudication—a
placebo-controlled, double-blind multicenter trial. VASA 1998;27:106–10.
28. Bauer U. Six-month double-blind randomised clinical trial of Ginkgo
biloba extract versus placebo in two parallel groups in patients suffering from peripheral
arterial insufficiency. Arzneimittelforsschung 1984;34:716–20 [in German].
29. Blume J, Kieser M, Hölscher U. Placebo-controlled, double-blind
study on the efficacy of Ginkgo biloba special extract EGb 761 in maximum-level
trained patients with intermittent claudication. Vasa 1996;25:265–74.
30. Blume J, Kieser M, Hölscher U. Efficacy of Ginkgo
biloba special extract EGb 761 in peripheral occlusive disease. Fortschr Med
1998;116:137–43.
31. Schweizer J, Hautmann C. Comparison of two dosages of Ginkgo
biloba extract EGb 761 in patients with peripheral arterial occlusive disease
Fontaine’s stage IIb. Arzneimittelforschung 1999;49:900–4.
32. Kiesewetter H, Jung F, Jung EM, et al. Effects of garlic coated
tablets in peripheral arterial occlusive disease. Clin Investig
1993;71:383–6.
33. Smulski HS, Wojcicki J. Placebo-controlled, double-blind trial to
determine the efficacy of the Tibetan plant preparation Padma 28 for intermittent
claudication. Altern Ther 1995;1(3):44–9.
34. Drabaek H, Mehlsen J, Himmelstrup H, Winther K. A botanical compound,
Padma 28, increases walking distance in stable intermittent claudication. Angiology
1993;44:863–7.